News|Videos|November 4, 2022
Asciminib vs Bosutinib in Chronic Myeloid Leukemia Treatment
Daniel DeAngelo, MD, PhD, presents data from a phase 3 study comparing asciminib and bosutinib after treatment with 2 or more prior TKIs in CML.
Advertisement
Episodes in this series
Advertisement
Related to this article
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma
5